NICE proposes further research for Sobi's Dupuytren to treat Dupuytren's contracture

The UK's National Institute for Health and Clinical Excellence (NICE) on Wednesday confirmed its earlier final draft guidance not to recommend collagenase clostridium histolyticum (Xiapex, from Swedish Orphan Biovitrum [STO: SOBI]), to treat Dupuytren’s contracture for routine use.

The medicines cost-effectiveness body has instead recommended further research.

Professor Carole Longson, director of the Centre for Health Technology Evaluation at the NICE, said: “The independent Committee felt the treatment is innovative and shows real promise, particularly in people with moderate disease. However, the Committee agreed with comments from patients and clinicians that further research into the clinical effectiveness of collagenase clostridium histolyticum compared with other treatments for Dupuytren’s contracture is needed before NICE is able to determine whether it represents a clinically and cost effective option for routine use in the NHS.”